This article was funded by Partner Therapeutics. Unrelated to this manuscript, A Tarhini has received consulting fees for consulting and/or advisory board participation from Partner Therapeutics, Merck, Bristol Myers Squibb, Novartis, Genentech-Roche, Array Biopharma, Sanofi-Genzyme/Regeneron, Pfizer, EMD Serono, NewLink Genetics, BioNTech, Immunocore and Eisai; participated in a Data Safety Monitoring Board for Incyte; and has been involved with institution contracted research with Merck, OncoSec, Genentech-Roche, Bristol Myers Squibb and Clinigen within the last 3 years. I Joshi and F Garner are employees of and have stock options for Partner Therapeutics. F Garner owns stock for Constellation Pharmaceutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was funded by Partner Therapeutics.